As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...
Investor's Business Daily on MSN5h
Bristol Myers Stock: This Covered Call Could Enhance Your Return Beyond A 4% Dividend YieldBristol Myers Squibb has been a strong performer in the six months, rising over 23% in that time. Investors desiring to ...
We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...
Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...
But what it does have is its critical role—albeit underrated—as a biotech hub. Competing with South San Francisco and Boston, ...
Lexicon Pharmaceuticals and Bristol-Myers Squibb, though both in pharma, are leagues apart in scale, profitability, and risk.
Bristol-Myers Squibb finds itself in the billionaire investors’ bargain bin, but with some surprisingly luxe packaging. The ...
Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
Pharmaceutical company Novartis is laying off more than 400 US employees who report to its East Hanover facility as part of a ...
Vermont Business Magazine Howard Center announces its spring conference, Perspectives 2025: Confronting Stigma, Cultivating Compassion, on May 13, 2025, from 8:30 a.m. to 4:30 p.m. This year's event ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback